208 related articles for article (PubMed ID: 33735501)
1. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
[TBL] [Abstract][Full Text] [Related]
2. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
[TBL] [Abstract][Full Text] [Related]
3. A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (
Ukaji T; Takemoto A; Katayama R; Takeuchi K; Fujita N
Oncotarget; 2018 Sep; 9(70):33322-33336. PubMed ID: 30279963
[TBL] [Abstract][Full Text] [Related]
4. Platelet-activating factor podoplanin: from discovery to drug development.
Takemoto A; Miyata K; Fujita N
Cancer Metastasis Rev; 2017 Jun; 36(2):225-234. PubMed ID: 28674748
[TBL] [Abstract][Full Text] [Related]
5. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
[TBL] [Abstract][Full Text] [Related]
6. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.
Kaneko MK; Kunita A; Abe S; Tsujimoto Y; Fukayama M; Goto K; Sawa Y; Nishioka Y; Kato Y
Cancer Sci; 2012 Nov; 103(11):1913-9. PubMed ID: 22816430
[TBL] [Abstract][Full Text] [Related]
7. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.
Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP
Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756
[TBL] [Abstract][Full Text] [Related]
10. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
12. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
Sheng M; Sun R; Fu J; Lu G
BMC Cancer; 2024 Apr; 24(1):399. PubMed ID: 38561690
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
14. Development of Monoclonal Antibody LpMab-10 Recognizing Non-glycosylated PLAG1/2 Domain Including Thr34 of Human Podoplanin.
Ogasawara S; Oki H; Kaneko MK; Hozumi Y; Liu X; Honma R; Fujii Y; Nakamura T; Goto K; Takagi M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):318-26. PubMed ID: 26492619
[TBL] [Abstract][Full Text] [Related]
15. Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin.
Kato Y; Ogasawara S; Oki H; Honma R; Takagi M; Fujii Y; Nakamura T; Saidoh N; Kanno H; Umetsu M; Kamata S; Kubo H; Yamada M; Sawa Y; Morita K; Harada H; Suzuki H; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2016 Apr; 35(2):109-16. PubMed ID: 26937552
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
[TBL] [Abstract][Full Text] [Related]
17. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
[TBL] [Abstract][Full Text] [Related]
20. Targeting Podoplanin for the Treatment of Osteosarcoma.
Takemoto A; Takagi S; Ukaji T; Gyobu N; Kakino M; Takami M; Kobayashi A; Lebel M; Kawaguchi T; Sugawara M; Tsuji-Takayama K; Ichihara K; Funauchi Y; Ae K; Matsumoto S; Sugiura Y; Takeuchi K; Noda T; Katayama R; Fujita N
Clin Cancer Res; 2022 Jun; 28(12):2633-2645. PubMed ID: 35381070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
